A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

Single dose: Fasting, oral administration, as a single dose, taken with warm water. Multiple doses: Fasting, oral administration, as a single dose, taken with warm water, once daily (dosing frequency may be adjusted based on study data), with 28 days as one cycle.

Trial Details

NCT ID

NCT07361237

Phase

PHASE1

Sponsor

Tongji University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

HJ-004-02 tablets

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Male or female, aged \>=18 years and \<75 years
Clinical diagnosis of NSCLC.
Subjects must have experienced disease progression after standard therapy, or be intolerant to or unsuitable for standard therapy, or have no avail…
Subjects must provide 3-5 archived tumor tissue slides

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →